TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
Study: NCT00227994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL
Study: NCT01150383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise training with supplemental oxygen
Description: Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with oxygen supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed with oxygen supplementation.~After 6 weeks of intervention with oxygen supplementation, second intervention period will start with room air instead of oxygen supplementation (as described above).
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL
Study: NCT01150383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise training with room air supplementation
Description: Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with room air supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed under normoxic conditions.~After 6 weeks of intervention with room air, second intervention period will start with oxygen supplementation instead of room air (as described above).
Study: NCT05680389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg twice daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily for 3 months
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 12
Description: Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL
Study: NCT02890277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the high intensity focused ultrasound (Mianyang Sonic electronic LLC)
Study: NCT00904995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
Study: NCT02890277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).
Study: NCT03289143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semorinemab
Description: Participants will receive Semorinemab intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semorinemab
Description: Participants will receive Semorinemab intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semorinemab
Description: Participants will receive Semorinemab intravenously (IV).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo doses of Semorinemab given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [18F]GTP1
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Study: NCT02117778

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Nerve Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Nerve Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Nerve Block
Study: NCT03334838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)
Description: Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)
Description: Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.
Study: NCT02777086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StaySafe
Description: StaySafe is a self-administered tablet computer app designed to improve decision-making around health risk behaviors.
Study: NCT04407338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-DYN
Description: The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bolted fusion (with or without cage)
Description: The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
Study: NCT01508208

Intervention type: OTHER
Group type: OTHER
Intervention: Hypertensive disorder of pregnancy
Description: Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
Study: NCT04441697

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple sleep latency tests
Description: The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple sleep latency tests
Description: The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple sleep latency tests
Description: The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.
Study: NCT02472912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMO-2
Description: Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Humira
Description: Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-Humira
Description: Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).
Study: NCT03446898

Intervention type: OTHER
Intervention: Chronic hypoxic environment
Description: Chronic hypoxic environment. Since the partial pressure of oxygen in inspired air falls with increasing terrestrial elevation above sea level, many physiological variables in adults would be affected by the chronic hypoxia environment.
Study: NCT02859974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory retraining for PVFMD
Description: Patients serve as their own controls. During a three week baseline, participants will complete the Dyspnea Index (DI), and have their heart rate, Resp. minute volume and ETCO2 on days 1 and 21 (or on the day treatment commences). Participants will complete a daily log reporting their daily symptoms. This will serve as the baseline prephase.~Post 1 phase will include five individual therapy sessions teaching the respiratory retraining techniques over an estimated three week period.~Post2 phase will comprise of a six week home practice phase. There will be four measuring points per participant: pre1/pre2 measurements on day 1 and 21 (or on the day therapy begins), post1 upon completing five therapy sessions and post 2 upon completion of the home practice phase.
Study: NCT00339040

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)
Description: QHPV at week 0, 8, 24 and 96.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo/QHPV
Description: Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
Study: NCT01269684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
Study: NCT00940550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin
Description: 2 mg tablet, once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temazepam
Description: 20 mg capsule, once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: 10 mg capsule, once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match melatonin, zolpidem and temazepam
Description: Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
Study: NCT03130829

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligo Fucoidan
Description: Oral, twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, twice daily
Study: NCT00712517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol anesthesia 3-5mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: sevoflurane anesthesia
Study: NCT04474639

Intervention type: DEVICE
Intervention: echocardiographic examination
Description: conducting an echocardiographic study according to a standard protocol with the determination of diastolic dysfunction of the left ventricle

Intervention type: DEVICE
Intervention: echocardiographic examination
Description: conducting an echocardiographic study according to a standard protocol with the determination of diastolic dysfunction of the left ventricle
Study: NCT04221633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Early Engagement (E3) webinar
Description: Webinar-based training to provide information regarding evidence-based engagement strategies (e.g., motivational interviewing, McKay's engagement model), trauma, mental health screening, and identifying evidence-based mental health treatments for children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Early Engagement (E3) webinar
Description: Webinar-based training to provide information regarding evidence-based engagement strategies (e.g., motivational interviewing, McKay's engagement model), trauma, mental health screening, and identifying evidence-based mental health treatments for children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation for E3 training
Description: 10 consultation calls with experts in engagement, child trauma, and mental health screening to support the webinar training
Study: NCT03261895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Integrative health and wellness programme
Description: Participants in the intervention group will go through a eight-session structured education programme. The education programme was designed by incorporating the evidences of diabetes care from the western medicine and the philosophy of traditional Chinese medicine.
Study: NCT02538120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microvascular assessment
Description: Microvascular assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microvascular assessment
Description: Microvascular assessment
Study: NCT00819429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: 1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: 1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
Study: NCT00904995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: 6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.
Study: NCT00660777

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Deep breathing, bilateral alternate chewing, nasal lavage
Description: Deep breathing, bilateral alternate chewing, nasal lavage
Study: NCT00819429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment (or TAU in Child Guidance Clinic)
Description: Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment (or TAU in Child Guidance Clinic)
Description: Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment (or TAU in Child Guidance Clinic)
Description: Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment (or TAU in Child Guidance Clinic)
Description: Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
Study: NCT00660777

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal exercises
Description: Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
Study: NCT02764645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioGard Cannula
Description: CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.~The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22Fr curved Cannula
Description: arterial cannula for use in cardiac surgery
Study: NCT03046810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wellness toileting system
Description: This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
Study: NCT00477308

Intervention type: PROCEDURE
Group type: OTHER
Intervention: salvage therapy
Study: NCT03791892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder mobilization Group
Description: Suprascapular nerve block administered every week to both groups. Joint mobilization (3 sets / 40 seconds hold / 30 seconds interval) Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Strengthening exercises ( 3 sets / 15 reps)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment Group
Description: Suprascapular nerve block administered every week to both groups. Daily Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Daily Strengthening exercises ( 3 sets / 15 reps)